Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Therapeutic preclinical study on the synergy between CD73 inhibitors and selinexor for managing multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYan LiuSGShuang Gao

Discussion

Loading...

Member takes

Overview

Preclinical study shows combination therapy enhances cytotoxicity in multiple myeloma, indicating improved apoptosis rates.

Key Points

  • This research explores the effectiveness of combining CD73 inhibitors with selinexor for treating multiple myeloma.
  • Utilized gene-expression profiling of multiple myeloma cell lines to analyze CD73 regulation by selinexor.
  • Conducted experiments on BALB/c mice with J558 tumors, administering different treatment combinations.
  • Performed single-cell RNA sequencing to investigate immune-cell interactions and define tumor-immune crosstalk.
  • Utilized co-culture assays to measure tumor-cell killing by CD8+ T cells and the effects of CD73 blockade.
  • Combining CD73 inhibitors and selinexor decreased tumor burden by 62%, outperforming individual treatments.
  • Single-cell RNA sequencing indicated enhanced activation of CD8+ T cells with combination therapy.
  • Increased Granzyme B and IFN-γ secretion by CD8+ T cells was recorded with CD73 inhibition, supporting greater cytotoxicity.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1c9https://doi.org/10.1182/blood-2025-7455
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selinexor potentiates NK cell activation against multiple myeloma2026
  2. 2Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape2026 · 1 citations
  3. 3Synergistic effects of MALT1 inhibitor and selinexor on Acute Myeloid Leukemia cells and the underlying mechanisms2025
  4. 4A novel conditioning regimen combining selinexor with melphalan  Improves Survival in Patients with multiple myeloma:a prospective study2025
  5. 5Upregulation of BCMA expression by selinexor2025